Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Placebo
Drug: Clopidogrel

First Posted Date: 2010-05-04

Last Posted Date: 2012-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 282

Registration Number: NCT01115738

Locations: 🇮🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India

A Phase 1 Study in Participants With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Squamous Cell Carcinoma
Carcinoma, Squamous Cell of Head and Neck
Lung Squamous Cell Carcinoma Stage IV
Anal Squamous Cell Carcinoma
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Prexasertib

First Posted Date: 2010-05-04

Last Posted Date: 2016-05-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 150

Registration Number: NCT01115790

Locations: 🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 2 locations

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1

Terminated

Conditions: Neuroendocrine Tumors
Metastases, Neoplasm
Carcinoma, Non-small Cell Lung
Renal Cell Carcinoma

Interventions: Drug: LY2584702
Drug: Erlotinib
Drug: Everolimus

First Posted Date: 2010-05-04

Last Posted Date: 2019-02-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT01115803

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villejuif, France

A Study in Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Metastases, Neoplasm

Interventions: Drug: LY2780301

First Posted Date: 2010-05-04

Last Posted Date: 2012-07-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT01115751

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain

A Study in Participants With Diabetic Kidney Disease

Phase 2

Terminated

Conditions: Diabetic Kidney Disease
Diabetic Nephropathy
Diabetic Glomerulosclerosis

Interventions: Drug: LY2382770
Drug: Placebo

First Posted Date: 2010-04-30

Last Posted Date: 2019-09-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 417

Registration Number: NCT01113801

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Phase 2

Completed

Conditions: Colon Cancer
Rectal Cancer

Interventions: Biological: Icrucumab
Biological: Ramucirumab
Drug: mFOLFOX-6

First Posted Date: 2010-04-27

Last Posted Date: 2019-08-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 158

Registration Number: NCT01111604

Locations: 🇨🇦
ImClone Investigational Site, Montreal, Quebec, Canada

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin lispro 2 day reservoir in-use
Drug: Insulin lispro 6 day reservoir in-use
Drug: Insulin aspart 6 day reservoir in-use

First Posted Date: 2010-04-23

Last Posted Date: 2019-03-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 132

Registration Number: NCT01109316

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Neoplasms
Carcinoma
Cancer of the Lung
Non-Small-Cell Lung Carcinoma

Interventions: Drug: Cetuximab
Drug: Cisplatin
Drug: Vinorelbine

First Posted Date: 2010-04-23

Last Posted Date: 2015-12-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01109524

Locations: 🇺🇸
Cancer Care Institute, Los Angeles, California, United States
🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸
Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States

and more 19 locations

Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: clopidogrel
Drug: prasugrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-10-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 155

Registration Number: NCT01107912

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden

Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: prasugrel
Drug: clopidogrel

First Posted Date: 2010-04-21

Last Posted Date: 2012-08-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT01107925

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy